Relapsed/Refractory Multiple Myeloma: Emerging Combination Strategies With Talquetamab

Description - Dr. Ajai Chari and Dr. Rahul Banerjee explore future directions for talquetamab in relapsed/refractory multiple myeloma (RRMM), focusing on emerging combination strategies designed to enhance the activity of T-cell–redirecting therapies. The discussion highlights the scientific rationale for combining talquetamab, a GPRC5D-directed bispecific antibody, with BCMA-targeted therapies such as teclistamab. The faculty review early clinical findings suggesting that dual-targeting approaches may help address disease heterogeneity and potentially improve outcomes in patient populations with historically poor prognoses, including those with extramedullary disease. Dr. Banerjee discusses data from studies evaluating talquetamab plus teclistamab, emphasizing encouraging response durability and disease control in challenging clinical settings. Dr. Chari and Dr. Banerjee also examine the broader concept of moving effective T-cell–redirecting therapies earlier in the treatment paradigm and discuss how combination approaches may help reduce attrition by providing patients access to highly active therapies before disease progression limits future treatment opportunities. The segment concludes with a discussion of ongoing and future studies evaluating talquetamab-based combinations in RRMM.